Patents by Inventor Eva Dahlén

Eva Dahlén has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides
    Patent number: 11780928
    Abstract: The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: October 10, 2023
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
  • NOVEL BISPECIFIC POLYPEPTIDES AGAINST CD137
    Publication number: 20220213213
    Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.
    Type: Application
    Filed: September 23, 2021
    Publication date: July 7, 2022
    Inventors: Eva DAHLÉN, Peter ELLMARK, Christina FUREBRING, Per NORLÉN, Anna SÄLL, Laura von SCHANTZ, Niina VEITONMÄKI, Laura VARAS, Jessica PETERSSON, Sara FRITZELL
  • NOVEL POLYPEPTIDES
    Publication number: 20210238298
    Abstract: The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same.
    Type: Application
    Filed: April 13, 2021
    Publication date: August 5, 2021
    Inventors: Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
  • Polypeptides
    Patent number: 11008396
    Abstract: The present invention provides bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same. The first and/or second T cell target may be selected from the group consisting of OX40, CTLA-4, CD137, CD27, GITR and CD28.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: May 18, 2021
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Niina Veitonmaki, Laura Von Schantz
  • Polypeptides
    Patent number: 10774150
    Abstract: The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: September 15, 2020
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
  • NOVEL POLYPEPTIDES
    Publication number: 20200190208
    Abstract: The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same.
    Type: Application
    Filed: February 3, 2020
    Publication date: June 18, 2020
    Inventors: Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
  • NOVEL BISPECIFIC POLYPEPTIDES AGAINST CD137
    Publication number: 20190169308
    Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.
    Type: Application
    Filed: April 24, 2017
    Publication date: June 6, 2019
    Inventors: Eva Dahlén, Peter Ellmark, Christina Furebring, Per Norlén, Anna Säll, Laura von Schantz, Niina Veitonmäki, Laura Varas, Jessica Petersson, Sara Fritzell
  • Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen
    Publication number: 20190161555
    Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to OX40, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.
    Type: Application
    Filed: June 30, 2017
    Publication date: May 30, 2019
    Inventors: Peter Ellmark, Per Norlen, Jessica Petersson, Sara Fritzell, Eva Dahlen
  • NOVEL POLYPEPTIDES
    Publication number: 20180118841
    Abstract: The present invention provides bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same. The first and/or second T cell target may be selected from the group consisting of OX40, CTLA-4, CD137, CD27, GITR and CD28.
    Type: Application
    Filed: May 20, 2016
    Publication date: May 3, 2018
    Inventors: Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Niina Veitonmaki, Laura Von Schantz
  • CD86 variants with improved affinity for CTLA-4
    Patent number: 9834589
    Abstract: The invention provides a polypeptide that specifically binds to CTLA-4, particularly human CTLA-4.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 5, 2017
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Christina Furebring, Eva Dahlen